Boston Scientific Corp. Price Target Increased to $13.00 by Analysts at Barclays (BSX)
Barclays boosted their price objective on shares of Boston Scientific Corp. (NYSE:BSX) from $12.00 to $13.00 in a research note issued on Friday, Analyst Ratings Network.com reports. The firm currently has an “overweight” rating on the stock. Barclays’ price objective indicates a potential upside of 11.88% from the stock’s previous close.
Shares of Boston Scientific Corp. (NYSE:BSX) traded up 0.69% during mid-day trading on Friday, hitting $11.62. The stock had a trading volume of 16,792,788 shares. Boston Scientific Corp. has a 52 week low of $5.04 and a 52 week high of $12.16. The stock’s 50-day moving average is $11. and its 200-day moving average is $9.12. The company’s market cap is $15.604 billion.
Boston Scientific Corp. (NYSE:BSX) last posted its quarterly earnings results on Thursday, October 24th. The company reported $0.17 EPS for the quarter, beating the Thomson Reuters consensus estimate of $0.09 by $0.08. The company had revenue of $1.74 billion for the quarter, compared to the consensus estimate of $1.73 billion. During the same quarter in the prior year, the company posted $0.16 earnings per share. The company’s quarterly revenue was up .0% on a year-over-year basis. On average, analysts predict that Boston Scientific Corp. will post $0.44 earnings per share for the current fiscal year.
BSX has been the subject of a number of other recent research reports. Analysts at Deutsche Bank raised their price target on shares of Boston Scientific Corp. from $11.00 to $13.00 in a research note to investors on Friday. They now have a “hold” rating on the stock. Separately, analysts at Jefferies Group raised their price target on shares of Boston Scientific Corp. from $10.00 to $12.00 in a research note to investors on Friday. They now have a “hold” rating on the stock. Finally, analysts at Zacks reiterated a “neutral” rating on shares of Boston Scientific Corp. in a research note to investors on Wednesday, October 9th. They now have a $12.00 price target on the stock. Fifteen investment analysts have rated the stock with a hold rating and eight have given a buy rating to the stock. The stock presently has a consensus rating of “Hold” and a consensus target price of $10.10.
Boston Scientific Corporation is a developer, manufacturer and marketer of medical devices that are used in a range of interventional medical specialties.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.